CAINasdaqServices-Medical LaboratoriesFiscal year ends December 31
Caris Life Sciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$30.71+0.15 (+0.49%)
Close on Oct 19, 2026
- Market cap
- $8.69B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.79 (−2.51%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Caris Life Sciences, Inc. grew revenue 85.4% to $989.61M over the twelve months to Jun 30, 2026. Free cash flow was $123.96M.
Revenue
$989.61M
+85.4% vs. a year earlier
Operating income
$153.26M
TTM Q2 2026
Free cash flow
$123.96M
TTM Q2 2026
EPS, diluted
-$3.22
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $8.69B
- P/E ratio
- –
- Price to sales
- 8.78
- Price to book
- 14.68
- Dividend yield
- –
- Free cash flow yield
- 1.43%
Fundamentals
- Revenue
- $989.61M
- Net income
- $105.14M
- EPS, diluted
- -$3.22
- Free cash flow
- $123.96M
- Book value per share
- $2.09
- Diluted shares
- 283M
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Revenue
$989.61M+85.4% YoY
Operating income
$153.26M
Net income
$105.14M
EPS, diluted
–
Free cash flow
$123.96M
Reported periodTrailing twelve months